Comparative Pharmacology
Head-to-head clinical analysis: CORTEF ACETATE versus CYCLOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTEF ACETATE versus CYCLOCORT.
CORTEF ACETATE vs CYCLOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressant activity; binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Adult: 5-60 mg orally every 6-12 hours (hydrocortisone base equivalent), or 10-240 mg IV/IM every 12 hours (as hydrocortisone sodium succinate). Dose depends on severity and condition.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
None Documented
None Documented
Plasma terminal half-life is approximately 1.5-2 hours. However, biologic half-life (duration of adrenal suppression) is 18-36 hours due to intracellular receptor binding.
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Primarily renal as inactive metabolites; less than 5% unchanged. Biliary/fecal elimination is minimal (<2%).
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid